Merck’s Zerbaxa (ceftolozane and tazobactam) Receives FDA’s Approval for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia in Adults

 Merck’s Zerbaxa (ceftolozane and tazobactam) Receives FDA’s Approval for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia in Adults

Merck’s Zerbaxa (ceftolozane and tazobactam) Receives FDA’s Approval for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia in Adults

Shots:

  • The approval is based on P-III ASPECT-NP study results assessing Zerbaxa (3gm, IV every 8hrs.) vs meropenem (1gm, IV, every 8hrs.) in 726 patients with HABP/VABP on mechanical ventilation aged ≥18yrs.
  • The P-III ASPECT-NP study results demonstrated that Zerbaxa is superior to meropenem for 28-day all-cause mortality (24% vs 25.3%), clinical response at Test-of-Cure (54.4% vs 53.3%)
  • Zerbaxa is a combination therapy of anti-bacterial & beta-lactamase inhibitor, act by reducing the development of drug-resistant bacteria and has received FDA’s Priority Review designation for preventing infection by susceptible Gram-negative microorganisms

Click here to read full press release/ article | Ref: Merck | Image: Creative Concept Design

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post